--- title: "10:01 ET\n\t\t\t\n\t\t\t\n\t\t\t\tBiobanking Market worth $11.82 billion by 2030 with 9.1% CAGR | MarketsandMarkets™" description: "The global Biobanking Market is projected to grow from US$7.16 billion in 2024 to US$11.82 billion by 2030, with a CAGR of 9.1%. Key growth drivers include the focus on personalized medicine, expandin" type: "news" locale: "en" url: "https://longbridge.com/en/news/254280644.md" published_at: "2025-08-23T14:04:45.000Z" --- # 10:01 ET Biobanking Market worth $11.82 billion by 2030 with 9.1% CAGR | MarketsandMarkets™ > The global Biobanking Market is projected to grow from US$7.16 billion in 2024 to US$11.82 billion by 2030, with a CAGR of 9.1%. Key growth drivers include the focus on personalized medicine, expanding cell and gene therapy pipelines, and automation in sample handling. The market is segmented by product into equipment and consumables, with freezers and refrigerators leading. The Asia Pacific region is expected to see the highest growth due to increased research capabilities. Major players include Thermo Fisher Scientific, Becton, Dickinson and Company, and Qiagen. , /PRNewswire/ -- The global **Biobanking Market**, valued at US$7.16 billion in 2024, stood at US$7.65 billion in 2025 and is projected to advance at a resilient CAGR of 9.1% from 2025 to 2030, culminating in a forecasted valuation of US$11.82 billion by the end of the period. Several factors contribute to the growth of the biobanking market, including growing focus on precision or personalized medicine, continuously expanding cell & gene therapy pipeline, and end-to-end automation for sample handling & storage. Additionally, the focus on sustainability and green-lab solutions offers growth opportunities for market players. However, long-term funding stability for public biobanks is a challenge faced by the market. **Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=594** **Browse in-depth TOC on '****Biobanking Market'** **350 - Tables ****45 - Figures ****300 - Pages** **By product,** the biobanking market is segmented into equipment and consumables. The equipment market is further split into freezers & refrigerators, temperature & humidity control systems, cryogenic storage systems, thawing equipment, alarm & monitoring systems, and other equipment. Freezers & refrigerators held the largest share of the biobanking equipment market in 2024 as they are essential to the core operations of any biobank, ensuring the long-term storage and preservation of biological samples such as blood, tissues, and DNA. Given the nature of biobank samples, maintaining optimal temperature conditions is critical to preserving sample integrity for future research, diagnostics, and therapeutic development. Cryogenic freezers, in particular, are indispensable for the preservation of cell lines, stem cells, and genetic materials, often requiring ultra-low temperatures to maintain viability for years. **By end users,** the biobanking services market is segmented into pharmaceutical & biotechnology companies & CROs, and academic & research institutes. The pharmaceutical & biotechnology companies & CROs segment is estimated to register the highest growth rate during the forecast period, driven by the rising demand for biologics, biosimilars, and advanced therapies such as cell and gene therapies. These companies are expanding their therapeutic offerings, which are dependent on cell lines, and clinical sample management is highly demanded by these end users. **By geography**, the biobanking market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to register the highest growth rate during the forecast period, since countries like China, India, and Japan ramp up their research capabilities, biobanks in the region are gaining momentum, becoming critical to advancing drug discovery, clinical trials, and population-based health studies. The growing prevalence of chronic diseases, coupled with the region's aging population, has spurred a need for comprehensive biobanking solutions to support healthcare innovations and research into disease prevention and treatment. **Request Sample Pages:** **https://www.marketsandmarkets.com/requestsampleNew.asp?id=594** The key players in the biobanking market include Thermo Fisher Scientific Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (BD) (US), Qiagen (Germany), Merck KGaA (Germany), Labcorp (US), Eurofins Scientific (Luxembourg), and Cryoport (US), among other players. **Thermo Fisher Scientific Inc. (US):** Thermo Fisher Scientific Inc. is a global leader in laboratory products and services, with a strong strategic position in the biobanking market, driven by its broad portfolio of advanced solutions for sample preservation, storage, and analysis. Its extensive product offering includes high-performance freezers, automated sample management systems, and consumables designed for biobanks. Thermo Fisher has strategically invested in expanding its biobanking solutions to support emerging areas such as precision medicine, genomics, and cell therapy. Its innovation strategy is underscored by its acquisition of companies like Life Technologies, which strengthened its capabilities in genomics and biopreservation, making it a key player in high throughput biobanking technologies. Additionally, its global presence, robust distribution network, and strong partnerships with biopharma and academic institutions place it in a prime position to meet the growing demands of biobanks worldwide. **Becton, Dickinson and Company (Germany)** BD has established a strong strategic position in the biobanking products market through its innovative solutions designed for sample collection, storage, and management. Its portfolio includes a wide range of specialized consumables, such as blood collection tubes, cryovials, and storage solutions, as well as advanced diagnostic systems that integrate with biobanks to enhance data tracking and sample integrity. The company's leadership in biobanking is further strengthened by its focus on developing cutting-edge technologies for blood-based diagnostics and sample handling, which is crucial for high-quality sample preservation. It has also invested in expanding its manufacturing and R&D capabilities, particularly in the US and Asia, positioning itself as a key player to support the growing needs of biobanks globally. Its strategic focus on automation and digitization has enabled it to offer integrated, scalable solutions that help biobanks streamline operations, reduce costs, and improve efficiency. **PHC Holdings (Germany)** PHC Holdings, through its subsidiary PHCbi, holds a strong strategic position in the biobanking products market by offering high-performance, energy-efficient freezers, refrigerators, and incubators tailored for biological sample preservation. With a long history of providing reliable and innovative solutions for life sciences and healthcare applications, PHC Holdings has gained significant traction in the biobanking sector, especially in the Asia Pacific region. Its focus on sustainable, eco-friendly products, including low-energy storage systems, aligns with the growing demand for greener technologies in the biobanking industry. Its expertise in cold storage technologies, combined with its ability to cater to the specific needs of biobanks, such as cryogenic storage and temperature monitoring, has strengthened its position as a trusted provider for biobanks worldwide. Furthermore, its ongoing investments in R&D and strategic expansions, such as the growing footprint in emerging markets, ensure continued relevance in the fast-evolving biobanking landscape. For more information, **Inquire Now!** **Related Reports:** **Biopreservation Market** **Lab Automation Market** **Regenerative Medicine Market** **Stem Cell Assays Market** **Nucleic Acid Isolation and Purification Market** Get access to the latest updates on **Biobanking Companies** and **Biobanking Market Size** **About MarketsandMarkets™:** MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, **80% of Fortune 2000 companies rely on MarketsandMarkets**, and **90 of the top 100 companies in each sector trust us to accelerate their revenue growth**. With a **global clientele of over 13,000 organizations**, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our **Market Intelligence Cloud, KnowledgeStore™**, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. **Contact: Mr. Rohan Salgarkar **MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: \[email protected\] Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets\_Logo.jpg SOURCE MarketsandMarkets ### Related Stocks - [TMO.US - Thermo Fisher Scentific](https://longbridge.com/en/quote/TMO.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 賽默飛世爾｜8-K：2025 財年 Q4 營收 122 億美元超過預期 | | [Link](https://longbridge.com/en/news/274138338.md) | | “醫藥春晚” 上，英偉達詳細論述 “AI 醫療怎麼幹” | 摩根大通表示，英偉達在 AI 醫療進行 “全棧式” 佈局，英偉達正在構建一個從芯片到工具再到領域模型的閉環，即所謂的 “幹實驗室 - 濕實驗室” 飛輪，同時 AI 正在從 “試點” 走向 “受僱”，美國醫療行業商業 AI 部署速度是整體經濟 | [Link](https://longbridge.com/en/news/272487651.md) | | 不敵川普施壓 蓋洛普停止追蹤總統支持率 | 美國蓋洛普宣佈停止追蹤總統支持率，結束自 1930 年代以來的慣例。此決定源於總統川普對民調機構的威脅，稱虛假民調應視為刑事犯罪。蓋洛普表示，此舉是基於自身研究目標的策略性調整，強調將繼續進行嚴謹的研究，關注重大議題。川普的支持率自去年以來 | [Link](https://longbridge.com/en/news/275756953.md) | | KGI 凱基委任龍淵為財富管理董事總經理 鞏固競爭優勢 | KGI 凱基委任龍淵為財富管理董事總經理，標誌著其在財富管理業務的戰略性拓展。龍淵將常駐香港，負責推動財富諮詢業務及擴展產品分銷策略。他曾在滙豐等國際金融機構擔任重要職務，成功推動滙豐中國區的財富管理發展。此任命將提升凱基在國際財富管理的競 | [Link](https://longbridge.com/en/news/275614810.md) | | 星展初級職員獲一次性特別花紅 6000 元 去年內地客財管業務雙位數增 | 星展集團宣佈將向初級職位員工發放一次性特別花紅 6000 港元，以表彰他們在艱難環境中的貢獻。此次獎勵涵蓋全球超過 2.3 萬名員工，預計總額為 1800 萬坡元。星展香港去年盈利創新高，零售銀行及財富管理業務表現理想，尤其是內地客户的增長 | [Link](https://longbridge.com/en/news/275858279.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.